The share price of Mirati Therapeutics, Inc. (MRTX) now
Latest session on the 5th of December for
Mirati Therapeutics, Inc. is negative
Trading Volume: 818088
Open: 56.84 /
High: 56.92 /
Low: 56.65
What analysts predict: $60.69
52-week High/Low: $80.3 / $27.3
50/200 Day Moving Average:
$53.93 / $42.75
This figure corresponds to the Average Price over the previous 50/200 days.
For Mirati Therapeutics stocks, the 50-day moving average is the support level today.
For Mirati Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Mirati Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio?
If yes, then on this page you will find useful information about the dynamics of the Mirati Therapeutics
stock price in 2024, 2025, 2026, 2027, 2028.
How much will one Mirati Therapeutics share be worth in
2024 - 2028?
When should I take profit in Mirati Therapeutics stock?
When should I record a loss on Mirati Therapeutics stock?
What are analysts' forecasts for Mirati Therapeutics stock?
What is the future of Mirati Therapeutics stock?
We forecast Mirati Therapeutics stock performance using neural networks based on historical data on Mirati Therapeutics stocks.
Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Mirati Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals.
(Next month, 2024, 2025, 2026, 2027 and 2028)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Mirati Therapeutics shares. This happens once a day.
Historical and forecast chart of Mirati Therapeutics stock
The chart below shows the historical price of Mirati Therapeutics stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Mirati Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
Mirati Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is focused on developing a pipeline of targeted cancer drugs. The company is developing candidate products to combat genetic and immunological cancer promoters. Its clinical programs consist of two candidate products: MRTX849, a Kirsten rat sarcoma inhibitor (KRAS) G12C, and Sitravatinib, a multi-kinase inhibitor. His KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit the KRAS G12C mutations that are present in patients with non-small cell lung cancer (NSCLC), adenocarcinoma, colorectal cancer (CRC), pancreatic cancer, and several other intractable cancers. Sitravatinib is a spectrally selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs) including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
Trending Themes in the Healthcare Sector
Mirati Therapeutics daily forecast for a month
Date
Target
Pes.
Opt.
Vol., %
Dec 08
56.94
55.78
58.27
4.47
Dec 09
57.36
56.47
58.48
3.55
Dec 10
57.80
56.26
58.57
4.10
Dec 11
57.25
55.99
57.69
3.04
Dec 12
58.43
57.80
59.74
3.36
Dec 13
60.32
59.49
61.25
2.95
Dec 14
59.70
59.20
60.50
2.19
Dec 15
59.16
57.90
59.60
2.93
Dec 16
58.64
57.60
59.26
2.89
Dec 17
58.42
57.68
59.42
3.01
Dec 18
58.66
58.03
59.26
2.12
Dec 19
57.92
56.95
59.30
4.13
Dec 20
57.11
56.63
58.09
2.58
Dec 21
56.47
54.89
57.44
4.64
Dec 22
57.54
56.45
58.10
2.93
Dec 23
57.90
56.79
58.33
2.71
Dec 24
56.91
56.27
57.69
2.51
Dec 25
57.69
56.74
59.24
4.41
Dec 26
55.69
54.28
56.70
4.45
Dec 27
55.45
54.17
56.97
5.16
Dec 28
56.35
55.42
56.88
2.63
Dec 29
56.90
55.96
57.56
2.85
Dec 30
57.00
56.00
57.94
3.46
Dec 31
56.38
55.06
57.52
4.48
Jan 01
57.94
56.74
59.46
4.79
Jan 02
58.55
57.22
59.55
4.08
Jan 03
57.03
56.59
58.33
3.07
Jan 04
57.71
57.18
58.38
2.08
Jan 05
56.66
56.00
57.71
3.05
Jan 06
56.62
55.69
57.21
2.74
Mirati Therapeutics Daily Price Targets
Mirati Therapeutics Stock Forecast 12-08-2023.
Forecast target price for 12-08-2023: $56.94. Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 4.275%. Pessimistic target level: 55.78 Optimistic target level: 58.27
Mirati Therapeutics Stock Forecast 12-09-2023.
Forecast target price for 12-09-2023: $57.36. Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.433%. Pessimistic target level: 56.47 Optimistic target level: 58.48
Mirati Therapeutics Stock Forecast 12-10-2023.
Forecast target price for 12-10-2023: $57.80. Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.938%. Pessimistic target level: 56.26 Optimistic target level: 58.57
Mirati Therapeutics Stock Forecast 12-11-2023.
Forecast target price for 12-11-2023: $57.25. Negative dynamics for Mirati Therapeutics shares will prevail with possible volatility of 2.952%. Pessimistic target level: 55.99 Optimistic target level: 57.69
Mirati Therapeutics Stock Forecast 12-12-2023.
Forecast target price for 12-12-2023: $58.43. Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 3.252%. Pessimistic target level: 57.80 Optimistic target level: 59.74
Mirati Therapeutics Stock Forecast 12-13-2023.
Forecast target price for 12-13-2023: $60.32. Positive dynamics for Mirati Therapeutics shares will prevail with possible volatility of 2.861%. Pessimistic target level: 59.49 Optimistic target level: 61.25
9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, US
Market Capitalization:
4 004 031 000 $
Market capitalization of the Mirati Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula
multiplying the number of MRTX shares in the company outstanding by the market price of one share.
EBITDA:
-760 681 984 $
EBITDA of Mirati Therapeutics is earnings before interest, income tax and depreciation of assets.
PE Ratio:
None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio:
N/A
Price/earnings to growth
DPS:
N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY:
N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS:
-12.18
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY:
N/A
Quarterly Revenue Growth YOY:
2.02
Trailing PE:
-
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE:
-
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue:
113.06
Enterprise Value (EV) /Revenue
EV To EBITDA:
-3.969
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding:
70148000
Number of issued ordinary shares
Shares Float:
N/A
Number of freely tradable shares
Shares Short Prior Month:
N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and,
moreover, are not trading signals.
When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market
as a result of using the information contained on the site.
This website uses cookies to ensure you get the best experience on our website